JP2020535144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535144A5 JP2020535144A5 JP2020516857A JP2020516857A JP2020535144A5 JP 2020535144 A5 JP2020535144 A5 JP 2020535144A5 JP 2020516857 A JP2020516857 A JP 2020516857A JP 2020516857 A JP2020516857 A JP 2020516857A JP 2020535144 A5 JP2020535144 A5 JP 2020535144A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- inhibitor
- pharmaceutical composition
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 19
- 239000012270 PD-1 inhibitor Substances 0.000 claims 18
- 239000012668 PD-1-inhibitor Substances 0.000 claims 18
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 18
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 7
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229940125429 CCR2 chemokine receptor antagonist Drugs 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- -1 O-R u Chemical group 0.000 claims 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000002025 prostate sarcoma Diseases 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 C[C@@](C*(CC1)[C@](CC2)C*=C2C(*(Cc2cc(N)c3)COc2c3N)=O)*1c(cc1)cc(C(*)=O)c1N Chemical compound C[C@@](C*(CC1)[C@](CC2)C*=C2C(*(Cc2cc(N)c3)COc2c3N)=O)*1c(cc1)cc(C(*)=O)c1N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023168563A JP2023181168A (ja) | 2017-09-25 | 2023-09-28 | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562952P | 2017-09-25 | 2017-09-25 | |
| US62/562,952 | 2017-09-25 | ||
| PCT/US2018/052408 WO2019060820A1 (en) | 2017-09-25 | 2018-09-24 | POLYTHERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023168563A Division JP2023181168A (ja) | 2017-09-25 | 2023-09-28 | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535144A JP2020535144A (ja) | 2020-12-03 |
| JP2020535144A5 true JP2020535144A5 (enExample) | 2021-11-04 |
| JP7453139B2 JP7453139B2 (ja) | 2024-03-19 |
Family
ID=65810578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516857A Active JP7453139B2 (ja) | 2017-09-25 | 2018-09-24 | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
| JP2023168563A Pending JP2023181168A (ja) | 2017-09-25 | 2023-09-28 | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023168563A Pending JP2023181168A (ja) | 2017-09-25 | 2023-09-28 | ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11304952B2 (enExample) |
| EP (1) | EP3687525B1 (enExample) |
| JP (2) | JP7453139B2 (enExample) |
| KR (1) | KR102677442B1 (enExample) |
| CN (2) | CN111712242B (enExample) |
| AR (1) | AR112831A1 (enExample) |
| AU (2) | AU2018335486B8 (enExample) |
| BR (1) | BR112020005284A2 (enExample) |
| CA (1) | CA3075638A1 (enExample) |
| IL (1) | IL273188B2 (enExample) |
| MA (1) | MA50665A (enExample) |
| MX (1) | MX2020003192A (enExample) |
| SG (1) | SG11202002119QA (enExample) |
| TW (1) | TWI875682B (enExample) |
| WO (1) | WO2019060820A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135168B (zh) | 2015-05-21 | 2021-07-20 | 凯莫森特里克斯股份有限公司 | Ccr2调节剂 |
| US20190275015A1 (en) * | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | INDANAMINE AS PD-L1 ANTAGONISTS |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| AR034257A1 (es) | 2000-06-30 | 2004-02-18 | Du Pont Pharm Co | Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas |
| AU8334501A (en) | 2000-08-17 | 2002-02-25 | Merck & Co Inc | Cyclopentyl modulators of chemokine receptor activity |
| EP1604982A1 (en) | 2001-07-02 | 2005-12-14 | AstraZeneca AB | Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity |
| ATE404538T1 (de) | 2002-04-29 | 2008-08-15 | Merck & Co Inc | Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität |
| TWI262077B (en) | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2003092586A2 (en) | 2002-04-29 | 2003-11-13 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US7491737B2 (en) | 2002-10-30 | 2009-02-17 | Merck & Co., Inc. | Heterarylpiperidine modulators of chemokine receptor activity |
| AU2004215409B2 (en) | 2003-02-24 | 2008-11-20 | Merck Sharp & Dohme Corp. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| CA2519220A1 (en) | 2003-03-18 | 2004-09-30 | Merck & Co., Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
| AU2004231087B2 (en) | 2003-04-15 | 2007-01-04 | Merck Sharp & Dohme Corp. | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| WO2004094371A2 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
| UA81365C2 (en) | 2003-10-27 | 2007-12-25 | Merck & Co Inc | Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition |
| AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
| AU2004313486A1 (en) | 2004-01-02 | 2005-07-28 | Merck & Co., Inc. | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity |
| AU2005214319B2 (en) | 2004-02-12 | 2009-02-19 | Merck Sharp & Dohme Corp. | Amino heterocyclic modulators of chemokine receptor activity |
| CN1950085A (zh) | 2004-05-11 | 2007-04-18 | 因赛特公司 | 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺 |
| UY29219A1 (es) | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
| JP2008526861A (ja) | 2005-01-06 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | 炎症性障害を治療するための薬剤併用療法および医薬組成物 |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| KR101617050B1 (ko) | 2007-07-12 | 2016-05-02 | 케모센트릭스, 인크. | 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| CA2745969C (en) | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| KR20120061060A (ko) | 2009-04-16 | 2012-06-12 | 얀센 파마슈티카 엔.브이. | Ｃｃｒ2의 4-아제티디닐-1-헤테로아릴-사이클로헥산 길항제 |
| CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| ES2449379T3 (es) | 2010-02-09 | 2014-03-19 | Bristol-Myers Squibb Company | Derivados de bencilpirrolidinona como moduladores de la actividad de receptores de quimiocinas |
| JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| AU2011268375B2 (en) | 2010-06-17 | 2015-02-05 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| WO2012121361A1 (ja) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | ジスピロピロリジン誘導体 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102129636B1 (ko) | 2012-05-31 | 2020-07-03 | 제넨테크, 인크. | Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법 |
| HK1208236A1 (en) | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| CN105451770B (zh) | 2013-08-20 | 2020-02-07 | 默沙东公司 | 使用PD-1拮抗剂和dinaciclib的组合治疗癌症 |
| JP6417419B2 (ja) | 2013-09-04 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫調節剤として有用な化合物 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| BR112017003718B1 (pt) | 2014-09-11 | 2023-04-11 | Bristol-Myers Squibb Company | Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1 |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| CN108135168B (zh) | 2015-05-21 | 2021-07-20 | 凯莫森特里克斯股份有限公司 | Ccr2调节剂 |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10639284B2 (en) | 2016-06-27 | 2020-05-05 | Chemocentryx, Inc. | Immunomodulator compounds |
| CA3058944A1 (en) * | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| CA3088542A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
-
2018
- 2018-09-24 AR ARP180102736A patent/AR112831A1/es unknown
- 2018-09-24 SG SG11202002119QA patent/SG11202002119QA/en unknown
- 2018-09-24 US US16/139,745 patent/US11304952B2/en active Active
- 2018-09-24 JP JP2020516857A patent/JP7453139B2/ja active Active
- 2018-09-24 CN CN201880062100.3A patent/CN111712242B/zh active Active
- 2018-09-24 CN CN202311614899.1A patent/CN118267479A/zh active Pending
- 2018-09-24 MA MA050665A patent/MA50665A/fr unknown
- 2018-09-24 KR KR1020207011664A patent/KR102677442B1/ko active Active
- 2018-09-24 CA CA3075638A patent/CA3075638A1/en active Pending
- 2018-09-24 WO PCT/US2018/052408 patent/WO2019060820A1/en not_active Ceased
- 2018-09-24 AU AU2018335486A patent/AU2018335486B8/en active Active
- 2018-09-24 BR BR112020005284-1A patent/BR112020005284A2/pt unknown
- 2018-09-24 MX MX2020003192A patent/MX2020003192A/es unknown
- 2018-09-24 EP EP18857688.8A patent/EP3687525B1/en active Active
- 2018-09-24 IL IL273188A patent/IL273188B2/en unknown
- 2018-09-25 TW TW107133664A patent/TWI875682B/zh active
-
2022
- 2022-03-15 US US17/694,829 patent/US20230023075A1/en active Pending
-
2023
- 2023-09-28 JP JP2023168563A patent/JP2023181168A/ja active Pending
-
2024
- 2024-06-20 AU AU2024204212A patent/AU2024204212B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535144A5 (enExample) | ||
| AU766081B2 (en) | Phthalazine derivatives for treating inflammatory diseases | |
| JP2019527202A5 (enExample) | ||
| JP2020528905A5 (enExample) | ||
| ES2250200T3 (es) | Derivados de naftiridina. | |
| JP2019512505A5 (enExample) | ||
| JP2015508823A5 (enExample) | ||
| PT2943493T (pt) | Compostos terapêuticos para o tratamento de infecções virais | |
| JPH05503919A (ja) | 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制 | |
| GB1525958A (en) | 2-(heterocyclic substituted alkylsulphinyl)-benzimidazoles and their pharmaceutical compositions | |
| KR20170063948A (ko) | Wnt 신호전달 경로의 저해제로서 n-피리디닐 아세트아미드 유도체 | |
| KR920021514A (ko) | 피리딘 유도체, 이의 제법 및 용도 | |
| BR112020008499A2 (pt) | composição farmacêutica para prevenir ou tratar leucemia mieloide aguda ou câncer de mama metastático | |
| JP2019519586A5 (enExample) | ||
| JP2007515419A5 (enExample) | ||
| CN107001467A (zh) | C‑c趋化因子受体9型(ccr9)的抑制剂和抗alha4beta7整联蛋白阻断抗体的组合治疗 | |
| JPWO2020102096A5 (enExample) | ||
| JP2006522824A5 (enExample) | ||
| RU96102842A (ru) | Применение кумаринов и карбостирилов в качестве pla2-ингибиторов, новые кумарины и карбостирилы, способ их получения и лекарственные средства | |
| JP2020508356A5 (enExample) | ||
| EP1675834A1 (en) | Compounds, compositions, and methods | |
| US4457932A (en) | Anti-ulcer agents | |
| PH20392A (en) | Pyridobenzodiazepinones pharmaceutical compositions thereof and method of use thereof | |
| RU2020112755A (ru) | Комбинированная терапия с использованием антагониста хемокинового рецептора-2 (CCR2) и ингибитора PD-1/PD-L1 | |
| NO823766L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive pyridazinderivater. |